Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Net Income (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Net Income for 5 consecutive years, with -$9.8 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Net Income fell 33.36% year-over-year to -$9.8 million, compared with a TTM value of -$9.8 million through Dec 2025, up 70.04%, and an annual FY2025 reading of -$47.8 million, down 13.87% over the prior year.
  • Net Income was -$9.8 million for Q2 2025 at SAB Biotherapeutics, up from -$9.9 million in the prior quarter.
  • Across five years, Net Income topped out at $1.4 million in Q1 2021 and bottomed at -$22.9 million in Q4 2023.
  • Average Net Income over 5 years is -$7.1 million, with a median of -$7.1 million recorded in 2022.
  • The sharpest move saw Net Income crashed 845.93% in 2023, then surged 56.5% in 2024.
  • Year by year, Net Income stood at -$11.6 million in 2021, then soared by 32.05% to -$7.8 million in 2022, then plummeted by 191.21% to -$22.9 million in 2023, then skyrocketed by 56.5% to -$9.9 million in 2024, then grew by 1.61% to -$9.8 million in 2025.
  • Business Quant data shows Net Income for SABS at -$9.8 million in Q2 2025, -$9.9 million in Q4 2024, and -$10.3 million in Q3 2024.